Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1981 Jul;12(1):73–78. doi: 10.1111/j.1365-2125.1981.tb01857.x

The influence of age, smoking and hyperthyroidism on plasma propranolol steady state concentration.

J Feely, J Crooks, I H Stevenson
PMCID: PMC1401749  PMID: 6264937

Abstract

1 Plasma propranolol steady state concentration (Css) was determined during chronic dosage (160 mg/day) in 22 hyperthyroid patients (aged 16-75 years, 11 smokers, 11 non-smokers) and again following treatment when euthyroid. 2 There was a positive correlation between plasma propranolol Css and age in patients both when hyperthyroid (r = 0.74, P less than 0.01) and when euthyroid (r = 0.58, P less than 0.05). 3 Plasma propranolol Css in hyperthyroid patients were lower (P less than 0.05) in smokers than in non-smokers. 4 Following correction of hyperthyroidism there was a significant increase (P less than 0.01) in both the plasma propranolol Css and degree of plasma protein binding of propranolol. 5 Hyperthyroidism and smoking are known to increase the rate of drug metabolism and it is suggested that these variables may give rise to or accentuate an age related reduction in propranolol clearance.

Full text

PDF
73

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. CROOKS J., MURRAY I. P., WAYNE E. J. Statistical methods applied to the clinical diagnosis of thyrotoxicosis. Q J Med. 1959 Apr;28(110):211–234. [PubMed] [Google Scholar]
  2. Castleden C. M., George C. F. The effect of ageing on the hepatic clearance of propranolol. Br J Clin Pharmacol. 1979 Jan;7(1):49–54. doi: 10.1111/j.1365-2125.1979.tb00896.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Crooks J., O'Malley K., Stevenson I. H. Pharmacokinetics in the elderly. Clin Pharmacokinet. 1976;1(4):280–296. doi: 10.2165/00003088-197601040-00003. [DOI] [PubMed] [Google Scholar]
  4. Eichelbaum M. Drug metabolism in thyroid disease. Clin Pharmacokinet. 1976;1(5):339–350. doi: 10.2165/00003088-197601050-00002. [DOI] [PubMed] [Google Scholar]
  5. Feely J., Forrest A., Gunn A., Hamilton W., Stevenson I., Crooks J. Propranolol dosage in thyrotoxicosis. J Clin Endocrinol Metab. 1980 Sep;51(3):658–661. doi: 10.1210/jcem-51-3-658. [DOI] [PubMed] [Google Scholar]
  6. Greenblatt D. J., Koch-Weser J. Adverse reactions to beta-adrenergic receptor blocking drugs: a report from the Boston collaborative drug surveillance program. Drugs. 1974;7(1):118–129. doi: 10.2165/00003495-197407010-00008. [DOI] [PubMed] [Google Scholar]
  7. Greenblatt D. J., Koch-Weser J. Adverse reactions to propranolol in hospitalized medical patients: a report from the Boston Collaborative Drug Surveillance Program. Am Heart J. 1973 Oct;86(4):478–484. doi: 10.1016/0002-8703(73)90139-7. [DOI] [PubMed] [Google Scholar]
  8. Hayes M. J., Langman M. J., Short A. H. Changes in drug metabolism with increasing age: 1. warfarin binding and plasma proteins. Br J Clin Pharmacol. 1975 Feb;2(1):69–72. doi: 10.1111/j.1365-2125.1975.tb00474.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hayes M. J., Langman M. J., Short A. H. Changes in drug metabolism with increasing age: 2. phenytoin clearance and protein binding. Br J Clin Pharmacol. 1975 Feb;2(1):73–79. doi: 10.1111/j.1365-2125.1975.tb00475.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Houghton G. W., Richens A., Leighton M. Effect of age, height, weight and sex on serum phenytoin concentration in epileptic patients. Br J Clin Pharmacol. 1975 Jun;2(3):251–256. doi: 10.1111/j.1365-2125.1975.tb01583.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kelly J. G., McDevitt D. G. Plasma protein binding of propranolol and isoprenaline in hyperthyroidism and hypothyroidism. Br J Clin Pharmacol. 1978 Aug;6(2):123–127. doi: 10.1111/j.1365-2125.1978.tb00836.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Nies A., Robinson D. S., Friedman M. J., Green R., Cooper T. B., Ravaris C. L., Ives J. O. Relationship between age and tricyclic antidepressant plasma levels. Am J Psychiatry. 1977 Jul;134(7):790–793. doi: 10.1176/ajp.134.7.790. [DOI] [PubMed] [Google Scholar]
  13. Routledge P. A., Shand D. G. Clinical pharmacokinetics of propranolol. Clin Pharmacokinet. 1979 Mar-Apr;4(2):73–90. doi: 10.2165/00003088-197904020-00001. [DOI] [PubMed] [Google Scholar]
  14. Rubenfeld S., Silverman V. E., Welch K. M., Mallette L. E., Kohler P. O. Variable plasma propranolol levels in thyrotoxicosis. N Engl J Med. 1979 Feb 15;300(7):353–354. doi: 10.1056/NEJM197902153000707. [DOI] [PubMed] [Google Scholar]
  15. SHERLOCK S., BEARN A. G., BILLING B. H., PATERSON J. C. S. Splanchnic blood flow in man by the bromsulfalein method: the relation of peripheral plasma bromsulfalein level to the calculated flow. J Lab Clin Med. 1950 Jun;35(6):923–932. [PubMed] [Google Scholar]
  16. Schneider R. E., Bishop H., Yates R. A., Quarterman C. P., Kendall M. J. Effect of age on plasma propranolol levels. Br J Clin Pharmacol. 1980 Aug;10(2):169–171. doi: 10.1111/j.1365-2125.1980.tb01736.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Shand D. G. Individualization of propranolol therapy. Med Clin North Am. 1974 Sep;58(5):1063–1069. doi: 10.1016/s0025-7125(16)32102-2. [DOI] [PubMed] [Google Scholar]
  18. Vestal R. E., Norris A. H., Tobin J. D., Cohen B. H., Shock N. W., Andres R. Antipyrine metabolism in man: influence of age, alcohol, caffeine, and smoking. Clin Pharmacol Ther. 1975 Oct;18(4):425–432. doi: 10.1002/cpt1975184425. [DOI] [PubMed] [Google Scholar]
  19. Vestal R. E., Wood A. J., Branch R. A., Shand D. G., Wilkinson G. R. Effects of age and cigarette smoking on propranolol disposition. Clin Pharmacol Ther. 1979 Jul;26(1):8–15. doi: 10.1002/cpt19792618. [DOI] [PubMed] [Google Scholar]
  20. Vestal R. E., Wood A. J., Shand D. G. Reduced beta-adrenoceptor sensitivity in the elderly. Clin Pharmacol Ther. 1979 Aug;26(2):181–186. doi: 10.1002/cpt1979262181. [DOI] [PubMed] [Google Scholar]
  21. Walle T., Conradi E. C., Walle U. K., Fagan T. C., Gaffney T. E. The predictable relationship between plasma levels and dose during chronic propranolol therapy. Clin Pharmacol Ther. 1978 Dec;24(6):668–677. doi: 10.1002/cpt1978246668. [DOI] [PubMed] [Google Scholar]
  22. Walle T. GLC determination of propranolol, other beta-blocking drugs, and metabolites in biological fluids and tissues. J Pharm Sci. 1974 Dec;63(12):1885–1891. doi: 10.1002/jps.2600631212. [DOI] [PubMed] [Google Scholar]
  23. Wood A. J., Vestal R. E., Wilkinson G. R., Branch R. A., Shand D. G. Effect of aging and cigarette smoking on antipyrine and indocyanine green elimination. Clin Pharmacol Ther. 1979 Jul;26(1):16–20. doi: 10.1002/cpt197926116. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES